Samsung looks to expand CDMO biz with $22bn investment

By Flora Southey contact

- Last updated on GMT

(Image: Getty/ma-no)
(Image: Getty/ma-no)

Related tags: Samsung biologics, Samsung bioepis, South korea

Samsung plans to invest KRW 180 trillion into its various businesses over the next three years, including in biomanufacturing-focused Samsung BioLogics.

Led for the most part by Samsung Electronics, the investment is designed to boost “businesses that will drive future growth”, ​including in artificial intelligence, 5G, automotive electronic parts, and biopharmaceuticals. Of the KRW 180 trillion dedicated to investments in technology, more than two thirds will be spent in South Korea.

According to the firm, both its contract development and manufacturing organisation (CDMO) Samsung BioLogics and biosimilar business Samsung Bioepis have seen strong growth. The company will “continue to invest heavily in the businesses, including developing and manufacturing biosimilars to combat chronic and difficult-to-cure diseases,” ​the firm said in a statement​.

Samsung BioLogics will benefit from an undisclosed percentage of the $22bn investment, we were told.

“We do not have detailed plant how to use the money, but I can imagine additional expansion of facilities as well as the CDMO business,” ​said the spokesperson.

Samsung BioLogics has made a number of significant investments in manufacturing facilities of late, including in its third and largest plant, which was completed in December last year​. Most recently, the CDMO announced US license approval​ to create a monoclonal antibody (mAb) at its Plant 1 facility in Incheon, South Korea.

Employment boost

Samsung also announced the investment will create 40,000 new jobs over the next three years.

“This includes generating up to 20,000 additional new jobs on top of previous hiring plans, reflecting Samsung’s commitment to support youth employment.

“Along with the direct employment, the investment in Korea is expected to help induce approximately 700,000 jobs in related industries and businesses,”​ according to the firm.

This article has been updated to clarify that KRW 180 trillion of the total sum will be invested in technology.

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers

Follow us

Products

View more

Webinars